T-MC-Gal-MMAE

T-MC-Gal-MMAE is an investigational **antibody-drug conjugate (ADC)** composed of a monoclonal antibody linked to monomethyl auristatin E (MMAE), a highly potent cytotoxic payload that disrupts microtubule polymerization and inhibits cell division. The T-MC-Gal portion denotes the antibody component, which is assumed to selectively recognize a specific target antigen or glycan (the exact target for this conjugate is not specified in current public literature), linked to MMAE via a cleavable linker. Once the ADC binds its cellular antigen and is internalized, enzymatic cleavage releases MMAE inside the target cell, triggering cell death through disruption of microtubule dynamics. This kind of ADC is being developed primarily for targeted cancer therapy and leverages the precise delivery of a potent anti-mitotic agent to reduce off-target toxicity compared to free MMAE[1][3][7][15]. The precise developer, manufacturer, clinical indication, and target for T-MC-Gal-MMAE are not publicly identified, but its naming and structure follow established ADC conventions.